<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030105</url>
  </required_header>
  <id_info>
    <org_study_id>BPN14770-CNS-103</org_study_id>
    <nct_id>NCT03030105</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetra Discovery Partners</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tetra Discovery Partners</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to&#xD;
      evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive&#xD;
      impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and&#xD;
      additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 38 subjects will be enrolled into the study. The study duration will be up to 12&#xD;
      weeks with 6 weeks of single-dose Treatment Visits. The study will consist of a Screening&#xD;
      Visit (up to 28 days prior to first study drug administration), six inpatient Treatment&#xD;
      Visits (Periods 1 through 6), and a Follow-Up/Early Termination Visit (7-10 days after the&#xD;
      last dose of study medication). An additional study visit may be necessary to complete the&#xD;
      required cognitive test familiarization if not completed during the Screening Visit. Each&#xD;
      Treatment Visit will occur approximately one week apart, allowing a 6 to 8 day washout&#xD;
      period.&#xD;
&#xD;
      Subjects will be randomized to 1 of 6 treatment sequences based on a computer-generated&#xD;
      randomization schedule. Subjects will receive all 6 treatments as specified by the treatment&#xD;
      sequence according to a 6 × 6 Williams Latin square design. The following treatments will be&#xD;
      administered:&#xD;
&#xD;
      A. Scopolamine placebo + BPN14770 placebo + donepezil placebo&#xD;
&#xD;
      B. Scopolamine 0.5 mg + BPN14770 placebo + donepezil placebo&#xD;
&#xD;
      C. Scopolamine 0.5 mg + BPN14770 10 mg + donepezil placebo&#xD;
&#xD;
      D. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil placebo&#xD;
&#xD;
      E. Scopolamine 0.5 mg + donepezil 10 mg +BPN14770 placebo&#xD;
&#xD;
      F. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil 10 mg&#xD;
&#xD;
      During each of the Treatment Visits (Periods 1 through 6), subjects will be admitted to the&#xD;
      Clinical Research Unit (CRU) the day prior to each study drug administration (Day -1) and&#xD;
      discharged the day after study drug administration (Day 2). On the morning of study drug&#xD;
      administration (Day 1), subjects will be given study drug (BPN14770, donepezil, or placebo)&#xD;
      with 240mL of room temperature water 2 hours prior to the scopolamine or scopolamine placebo&#xD;
      sc injection. The timing for study drug administration will be referred to as t-2 (Hour -2).&#xD;
      Breakfast should be available approximately 30 minutes following the morning drug&#xD;
      administration. Two hours after study drug administration, the scopolamine or scopolamine&#xD;
      placebo sc injection will be administered. The time at which the scopolamine or scopolamine&#xD;
      placebo sc injection is administered will be referred to as t0 (Hour 0).&#xD;
&#xD;
      Cognitive testing will be performed 30 minutes prior to treatment with scopolamine injection&#xD;
      and at hours 1, 2, 3, 4, and 6 post-scopolamine injection.&#xD;
&#xD;
      PK samples will be collected during the treatment period to confirm study drug is present.&#xD;
&#xD;
      Safety assessments throughout the study will include physical exams, ECGs, vital signs,&#xD;
      chemistry, hematology, and urinalysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groton Maze Learning Test (GMLT)</measure>
    <time_frame>2 hours post-scopolamine s.c. injection</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Detection Test (DET)</measure>
    <time_frame>30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>One Card Learning Test (OCL)</measure>
    <time_frame>30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>One Back Test (ONB)</measure>
    <time_frame>30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Two Back Test (TWOB)</measure>
    <time_frame>30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical exam, vital signs, clinical laboratory, ECG</measure>
    <time_frame>Study duration up to 12 weeks</time_frame>
    <description>To evaluate the safety and tolerability of BPN14770 in healthy subjects</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of BPN14770</measure>
    <time_frame>Plasma BPN14770 concentrations at 0, 2.5, 4.5 and 6.5 hours post-scopolamine sc injection</time_frame>
    <description>To obtain pharmacokinetic data on BPN14770</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>A) P:P:P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Scopolamine placebo : BPN14770 placebo : Donepezil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B) S:P:P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) S:B:P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D) S:B:P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E) S:P:D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F) S:B:D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPN14770</intervention_name>
    <description>investigational drug</description>
    <arm_group_label>C) S:B:P</arm_group_label>
    <arm_group_label>D) S:B:P</arm_group_label>
    <arm_group_label>F) S:B:D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPN14770 placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>A) P:P:P</arm_group_label>
    <arm_group_label>B) S:P:P</arm_group_label>
    <arm_group_label>E) S:P:D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>comparator</description>
    <arm_group_label>E) S:P:D</arm_group_label>
    <arm_group_label>F) S:B:D</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>A) P:P:P</arm_group_label>
    <arm_group_label>B) S:P:P</arm_group_label>
    <arm_group_label>C) S:B:P</arm_group_label>
    <arm_group_label>D) S:B:P</arm_group_label>
    <other_name>Aricept placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine 0.6 MG/ML</intervention_name>
    <description>cognition impairment</description>
    <arm_group_label>B) S:P:P</arm_group_label>
    <arm_group_label>C) S:B:P</arm_group_label>
    <arm_group_label>D) S:B:P</arm_group_label>
    <arm_group_label>E) S:P:D</arm_group_label>
    <arm_group_label>F) S:B:D</arm_group_label>
    <other_name>Hyoscine s.c.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>A) P:P:P</arm_group_label>
    <other_name>Hyoscine s.c. placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or females between the ages of 18 to 55 years at Screening.&#xD;
&#xD;
          2. Body mass index between 18 kg/m2 to 33 kg/m2, inclusive, and body weight of &gt;50 kg&#xD;
             (110 pounds).&#xD;
&#xD;
          3. Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or&#xD;
             bilateral oophorectomy at least 6 months prior to first study drug administration), at&#xD;
             least two years post-menopausal, or willing to either (1) utilize hormonal&#xD;
             contraception plus use one barrier method or (2) use two barrier methods of&#xD;
             contraception from initial screening until one month after taking the final dose.&#xD;
             Barrier methods of contraception include diaphragm, cervical cap, male condom, female&#xD;
             condom, and spermicidal foam and sponges. An intrauterine device (IUD) is also&#xD;
             considered a barrier method of contraception in this study; if the subject is using an&#xD;
             IUD, she will need to use an additional barrier method of contraception. Menopausal&#xD;
             status will be verified by testing for follicle stimulating hormone (FSH ≥25 mIU/mL)&#xD;
             at Screening. In addition, all females must have a negative blood test for pregnancy&#xD;
             within 28 days during the Screening period and negative urine test for pregnancy on&#xD;
             Day-1 of each Treatment Visit regardless of childbearing potential.&#xD;
&#xD;
          4. Male subjects must be willing to inform female partners of their participation in the&#xD;
             study and must agree to use adequate contraceptive methods (vasectomy performed at&#xD;
             least 6 months prior to first study drug administration, or use at least one barrier&#xD;
             method of birth control).&#xD;
&#xD;
          5. Able to understand the study procedures, voluntarily consent to participate in this&#xD;
             study, and provide written informed consent prior to start of any study-specific&#xD;
             procedures.&#xD;
&#xD;
          6. Willing and able to remain in the study unit for the required periods and return for&#xD;
             each treatment of the six treatment periods, including the outpatient visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormality, in the Investigator's judgement, in Screening&#xD;
             hematology, chemistry, or urinalysis tests, or from medical history, social history,&#xD;
             vital sign, or physical examination&#xD;
&#xD;
          2. Active liver disease or positive serology results for hepatitis B surface antigen&#xD;
             (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).&#xD;
&#xD;
          3. Abnormal liver function test at the Screening Visit (aspartate aminotransferase or&#xD;
             alanine aminotransferase &gt;2 × the upper limit of normal [ULN]; total bilirubin &gt;1.5 ×&#xD;
             ULN; or alkaline phosphatase &gt;2 × ULN based on appropriate age and gender normal&#xD;
             values).&#xD;
&#xD;
          4. Current or past history of angle closure glaucoma, or diagnosis of angle closure&#xD;
             glaucoma.&#xD;
&#xD;
          5. Marked hypotension (systolic blood pressure [BP] ˂90 mmHg or diastolic BP ˂50 mmHg) or&#xD;
             hypertension (systolic BP ˃150 mmHg or diastolic BP ˃100 mmHg) based on sitting values&#xD;
             obtained. Out-of-range results may be repeated once at Screening. This exclusion&#xD;
             applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.&#xD;
&#xD;
          6. Marked bradycardia (heart rate ˂45 beats per minute [bpm]) or tachycardia (heart rate&#xD;
             ˃110 bpm) based on supine ECG values obtained. Out-of-range results may be repeated&#xD;
             once at Screening. This exclusion applies to the vital signs performed at Screening&#xD;
             and on Day -1 on Treatment Period 1.&#xD;
&#xD;
          7. Current or past history of significant (in the Investigator's judgement)&#xD;
             cardiovascular, cerebrovascular, pulmonary, renal, or liver disease. Stable,&#xD;
             well-controlled hypertension and hyperlipidemias are allowed.&#xD;
&#xD;
          8. Clinically important or significant conduction abnormalities on single ECG or evidence&#xD;
             or history of long QT syndrome based on supine ECG values obtained at Screening.&#xD;
             Out-of-range results may be repeated once at Screening.&#xD;
&#xD;
          9. Current or past history of gastric or duodenal ulcers or other diseases of the&#xD;
             gastrointestinal tract that could interfere with absorption of study drug. Note:&#xD;
             Subjects with a history of appendectomy or cholecystectomy may be enrolled.&#xD;
&#xD;
         10. Active acute or chronic infectious diseases.&#xD;
&#xD;
         11. Unable to discontinue medications including anticholinergic agents, psychotropic&#xD;
             drugs, sedative antihistamines, or other centrally active medications [e.g., CNS-&#xD;
             penetrant beta blockers], and moderate to strong inhibitors or inducers of CYP3A4,&#xD;
             CYP2D6, or other cytochromes) 14 days prior to the first dose of study drug (Period 1,&#xD;
             Day 1) and during the study (Follow-Up). Other prescription or non-prescription drugs&#xD;
             such as antihypertensive or cholesterol lowering drugs are allowed, if, in the&#xD;
             Investigator's judgement, they would not interfere with the study medication or the&#xD;
             cognitive testing.&#xD;
&#xD;
         12. Unable to discontinue and abstain from over-the-counter, herbal preparations, dietary&#xD;
             supplements, nutraceuticals, vitamins and minerals at least 7 days prior to the first&#xD;
             dose of study drug and during the study. The one exception to this rule is&#xD;
             acetaminophen, which may be taken for minor ailments at doses up to 1000 mg per day.&#xD;
&#xD;
         13. Any history of alcohol or other substance abuse, including marijuana, within the&#xD;
             previous year prior to the Screening visit (per the current edition of the Diagnostic&#xD;
             and Statistical Manual of Mental Disorders, 5th Edition: DSM-5), or regular (daily)&#xD;
             consumption of alcohol exceeding two bottles of beer, or the equivalent amount of&#xD;
             other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled&#xD;
             spirits).&#xD;
&#xD;
         14. Any use of alcohol, grapefruit, marijuana, or other psychotropic agent within 12 hours&#xD;
             of admission into the CRU.&#xD;
&#xD;
         15. Active smokers or tobacco users (e.g., chew and snuff) who are unable to discontinue&#xD;
             tobacco use or nicotine-containing products (including e-cigarettes) at least 4 weeks&#xD;
             prior to Screening and to refrain from using during the study.&#xD;
&#xD;
         16. Inability or unwillingness to comply with the protocol or likely inability to complete&#xD;
             the study.&#xD;
&#xD;
         17. Participation in other clinical studies involving investigational drug within the&#xD;
             previous 30 days prior to the Screening Visit.&#xD;
&#xD;
         18. Donation of blood within the prior 4 weeks, or blood products within the prior 2&#xD;
             weeks, prior to first study drug administration.&#xD;
&#xD;
         19. Positive result for drugs of abuse, alcohol, or cotinine at Screening, or a positive&#xD;
             drug or alcohol (breath) result upon admission to CRU.&#xD;
&#xD;
         20. History of clinically significant drug allergy that includes symptoms such as&#xD;
             shortness of breath, rash, or edema. This includes known hypersensitivity to donepezil&#xD;
             hydrochloride, scopolamine, or belladonna, alkaloids.&#xD;
&#xD;
         21. Inability or unwillingness to perform the Cogstate cognitive function tests.&#xD;
&#xD;
         22. A suicidal ideation intensity score of 2 or higher per screening Columbia Suicide&#xD;
             Severity Rating Scale (C-SSRS) assessment and/or any suicidal behavior within the past&#xD;
             28 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassandra Key, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Early Phase Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>Dementia</keyword>
  <keyword>Phosphodiesterase Type 4D</keyword>
  <keyword>PDE4D</keyword>
  <keyword>Scopolamine</keyword>
  <keyword>Donepezil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

